Quanterix Reports $36.4M Revenue in Q1 2026, Driven by Product Growth and Acquisition

Quanterix Corporation reported a total revenue of $36.4 million for the first quarter of 2026, marking a 20% increase from $30.3 million in the same period of 2025. The growth was primarily driven by a 23% rise in product revenue, which reached $25.5 million, largely attributed to the acquisition of Akoya Biosciences, Inc. This acquisition contributed approximately $8.7 million to product revenue. However, the legacy Quanterix business experienced a decline in product revenue of $3.9 million, or 19%, due to reduced demand from academic and pharmaceutical customers amid a constrained funding environment. The company reported a net loss of $17.5 million for the quarter, a slight improvement from a net loss of $20.5 million in the prior year.

In terms of operational metrics, Quanterix's installed base of instruments exceeded 2,500, with over 6,500 scientific publications citing its technologies. The company continues to focus on expanding its research and development efforts, particularly in the Alzheimer’s diagnostics market, and has made strategic investments to enhance its commercial effectiveness. The company’s total operating expenses rose to $56.9 million, up from $41.2 million in the previous year, largely due to a $19.8 million impairment charge related to an in-process research and development asset following the termination of a development agreement with a biopharmaceutical customer.

Quanterix's cash and cash equivalents stood at $36.2 million as of March 31, 2026, alongside $63.1 million in marketable securities. The company reported net cash used in operating activities of $18.1 million for the quarter, an increase from $13.9 million in the same period last year. The increase in cash used was primarily due to non-cash adjustments related to the impairment charge and recognition of deferred revenue. The company anticipates achieving cash flow breakeven in the second half of 2026, contingent on the successful implementation of its strategic initiatives and market conditions.

The company has also made significant changes to its accounting policies, specifically regarding the classification of shipping and handling costs, which are now recorded in the cost of product revenue rather than in selling, general, and administrative expenses. This change is expected to better align costs with related revenues. Quanterix continues to evaluate its operational strategies and has streamlined its product roadmap to focus on initiatives that are expected to positively impact revenues starting in 2026.

Looking ahead, Quanterix is focused on enhancing its product offerings and expanding its market presence, particularly in the diagnostics sector. The company has submitted a 510(k) premarket notification to the FDA for a multi-analyte algorithmic blood test for Alzheimer’s disease, which has received Breakthrough Device Designation. This submission is a key milestone in the company’s strategy to provide innovative diagnostic tools and improve patient outcomes in the field of cognitive health.